Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 17/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.68 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884924 | 0.87 | PDE4D (0.68) | PDE4DPDE4APDE4BPDE4CSMN1; SMN2 | |
| SCHEMBL885207 | 0.84 | PDE4D (0.75) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL29373051 | 0.81 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL885153 | 0.81 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL885321 | 0.81 | PDE4D (0.70) | PDE4DPDE4APDE4BPDE4CSMN1; SMN2 | |
| SCHEMBL885122 | 0.81 | PDE4D (0.82) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL1434520 | 0.80 | PDE4D (0.78) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10194807 | 0.80 | PDE4D (0.69) | PDE4DPDE4APDE4BPDE4CSMN1; SMN2 | |
| SCHEMBL1434366 | 0.80 | PDE4D (0.64) | PDE4DPDE4APDE4BPDE4CSMN1; SMN2 | |
| SCHEMBL14480187 | 0.80 | PDE4D (0.69) | PDE4DPDE4APDE4BPDE4CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| US-8497380-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2013-07-30 | — | — | US | disclosed |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | FELDING JAKOB (DK) | 2013-01-10 | — | — | US | disclosed |
| US-8324394-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-12-04 | — | — | US | disclosed |
| US-20120165539-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | FELDING JAKOB (DK) | 2012-06-28 | — | — | US | disclosed |
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | disclosed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165539-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4D 9/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4D 8/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE3B, PDE5A | PDE4D 10/4885PDE4A 1/4885PDE4B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.